Real-world evidence on Gilead's HIV combo Biktarvy confirms high efficacy; Digital therapeutics firm to trade on Nasdaq
Gilead on Friday announced interim results from an ongoing, real-world trial for its HIV drug Biktarvy, confirming its effectiveness in more than 1,100 people living with HIV, and analyzing patient-reported outcomes too.
The FDA approved Biktarvy in 2018, based on data from four Phase III studies.
In this latest observational study, treatment with Biktarvy occurred between June 2018 and September 2020, and after 12 months of Biktarvy, the vast majority of treatment-naive adults and treatment-experienced adults living with HIV — 97% and 96%, respectively — achieved and maintained virologic suppression (HIV-1 RNA <50 copies/mL).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.